Alkermes plc. Effective Income Tax Rate Reconciliation, Tax Contingency, Percent
Alkermes plc. (ALKS) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Percent of 0.20% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies · last filed 2026-02-25
- Alkermes plc. effective income tax rate reconciliation, tax contingency, percent for fiscal 2025 was 0.20%.
- Alkermes plc. effective income tax rate reconciliation, tax contingency, percent for fiscal 2024 was -0.20%.
- Alkermes plc. effective income tax rate reconciliation, tax contingency, percent for fiscal 2023 was -0.10%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Percent 12 month |
|---|---|
| 2025-12-31 | 0.20% 10-K · filed 2026-02-25 |
| 2024-12-31 | -0.20% 10-K · filed 2026-02-25 |
| 2023-12-31 | -0.10% 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |